HomeAI · summaries
Storia in 7 fonti
FDA approves Orzeyful for type 1 narcolepsy in adults
The FDA has approved oveporexton for the treatment of narcolepsy type 1 in adults, according to officials with Takeda, the drug’s developer. Oveporexton (Orzeyful, Takeda), an oral orexin receptor 2 agonist, is the first medicine indicated in the U.S. to treat narcolepsy type 1 (NT1) holistically instead of treating individual symptoms, Takeda officials said in a press release.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Let the orexin market begin: Takeda snags FDA approval for narcolepsy type 1 drug
Takeda's Orzeyful wins FDA approval as the first full-symptom narcolepsy type 1 drug, kicking off an orexin agonist race with Lilly and Alkermes close behind.
- ·
morningstar.com
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
